Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group

Franco, Fernando; Aguiar-Bujanda, David; Miramón, José; Gumà, Josep; Álvarez, R.C. González; Gómez-Codina, José; Arroyo, F. Garcia; Llanos, Marta; Marín, Miguel; Alfaro, Jesús; Quero, Cristina; Delgado, Mayte; Nogales, Esteban; Menarguez, Francisco J.; Martı́nez, Natividad; Torrente, María; Royuela, Ana; Rodríguez-Abreu, Delvys; Provencio, Mariano

doi:10.1016/j.clml.2016.09.004

Cited by 33 publications

(49 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three reports published in China, Singapore, and Spain reported 3‐year overall survival rate of 59.5%, 77%, and 80%, respectively, compared to our study where our patients had a 3‐year overall survival rate of 64.3%. This is, however, keeping in mind that patients involved in the study in China and Spain were either stage IE or stage IIE . Therefore, our patients have fairly good prognosis.…”

Section: Discussioncontrasting

confidence: 69%

“…Primary breast lymphoma (PBL) is a rare entity of malignant breast tumours which represents about 0.5% of breast cancers and less than 1% of non‐Hodgkin's lymphoma . Breast lymphoma often closely resembles breast carcinoma, both clinically and radiologically …”

Section: Introductionmentioning

confidence: 99%

“…The commonest subtype of PBL is diffuse large B cell lymphoma (DLBCL) which consists of 40% to 70% of cases . Other subtypes include marginal zone lymphoma, follicular lymphoma, and mucosa‐associated lymphoid tissue (MALT) which are less common …”

Section: Introductionmentioning

confidence: 99%

“…Multiple modalities have been used for the treatment of PBL, including chemotherapy, radiotherapy, and surgical resection. It has been established that mastectomy does not confer any treatment benefit; hence, its use has declined since 1990s . Systemic chemotherapy remains the mainstay of treatment for PBL, with the consideration of adjuvant radiotherapy in patients with disease involvement in axillary lymph nodes …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Primary breast lymphoma: A single‐centre experience

et al. 2018

View full text Add to dashboard Cite

Background: Primary non-Hodgkin lymphoma is an extremely rare entity, and this condition represents less than 0.5% of all malignant lesions involving the mammary gland. As such, there has been a paucity of relevant clinical data arising from Southeast Asia. Aims:Our study aims to review the clinical presentation, diagnostic methods, treatment, and survival outcomes of all patients diagnosed with primary breast lymphoma in our institution between 2011 and 2017. Methods and results: Patients who had histologically proven lymphoma involving the breast were identified from a prospectively collected database in a single institution between 2011 and 2017. All seven patients were female, with a median age of 65 years old, and had presented with unilateral large breast or axillary masses. All the histological diagnosis was achieved with adequate tissue diagnosis either through core, incisional, or excisional biopsy. Five patients had diffuse large B cell lymphoma, one had marginal zone lymphoma, and the other had follicular lymphoma. Based on Ann Arbor classification, one patient had stage 1, three had stage 2, one with stage 3, and two patients with stage 4 disease. Five patients had received standard CHOP regimen with rituximab. At the time of analysis, patients who had nondisseminated disease had a median survival of 57 months. The overall mean survival time for all seven patients was 47 months. With the standard systemic chemotherapy treatment regimen, the estimated 3-year overall survival was found to be 64%. Conclusion: Primary breast lymphoma, though uncommon, may present in a similar manner as breast carcinomas, but the main treatment modality remains nonsurgical with systemic chemotherapy. Hence, it is prudent to obtain accurate histological diagnosis of primary breast lymphoma. In this study, our patients with nondisseminated breast lymphoma have demonstrated a fairly good survival outcome following chemotherapy.

show abstract

Section: Discussioncontrasting

confidence: 69%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Primary breast lymphoma: A single‐centre experience

et al. 2018

View full text Add to dashboard Cite

show abstract

“…For what concerns primary T-cell lymphoma of the breast, the 80% is represented by Ana- plastic Large Cell Lymphoma (ALLC), which could also be caused by breast implant in breast reconstruction [7] , [8] , and the remaining 20% by Hodgkin Lymphoma (LH) [9] , [10] .…”

Section: Discussionmentioning

confidence: 99%